It is the genome of an oncolytic virus, it is 34,000 base pairs long, and it is 100% artificial. It’s important because it not only has immediate application in studies of canine cancer, it also promises to inform the development of human therapies. In these human therapies, artificial viruses could be customized to such an extent, that they could qualify as personalized anticancer therapeutics. It is not the first time that oncolytic viruses has engineered but earlier virus like Herpes simplex and Oncorine(H101) are also being used. The virus in question in sCAV2, a conditionally replicative adenovirus (CRAd) that can target and kill tumor cells while sparing healthy cells. It was synthesized by scientists affiliated with Gen9, who worked in concert with scientists representing Autodesk and Auburn University. At Auburn, scientists led by Bruce Smith, V.M.D., Ph.D., intend to use the synthetic virus to evaluate therapeutic treatments in dogs with osteosarcoma, a